Overall verdict
Neutral
4.2/10
1-year performance
+38.71%
Score breakdown
Up 38.7% over 1 year, 89% of the 52-week range.
Strongest: Shareholder return 5.5/10. Weakest: Profitability 0.0/10.
28 analysts, target +0.0% vs the price.
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Descovy, Genvoya, Odefsey, Sunlenca, Symtuza, and YeztugoFor the treatment of HIV-1 infection in patients. It also provides Epclusa, Livdelzi, and Vemlidy to treat chronic hepatitis C virus, primary biliary cholangitis, and chronic hepatitis B virus ;
Tecartus, a T-cell therapy for the treatment of adult patients ; Trodelvy, an injection for intravenous use ; and Yescarta, a suspension for intravenous infusion, is a CAR T-cell therapy for the treatment of adult patients. Further, it provides AmBisome, for the treatment of serious invasive fungal infections; and Veklury for the treatment of COVID-19. Additionally, the company engages in the development of various immunotherapies for patients with cancer and other incurable diseases.
The company has collaboration agreements with Shenzhen Pregene Biopharma Co., Ltd. ; Abingworth ; Arcus Biosciences, Inc. ; Merck Sharp & Dohme Corp. ; Janssen Sciences Ireland Unlimited Company ; Japan Tobacco, Inc. ; Everest Medicines ; Merck & Co, Inc. ; Tentarix Biotherapeutics Inc. ; and Assembly Biosciences, Inc. It also has research collaboration, option, and license agreement with Merus N.V. for the discovery of novel dual tumor-associated antigens (TAA) targeting trispecific antibodies.
The company has a collaboration with Terray Therapeutics, Inc. to discover and develop small molecule therapies; and LEO Pharma to develop, manufacture, and commercialize the small molecule oral STAT6 program. The company has a partnership with Pan American Health Organization (PAHO) to accelerate access to lenacapavir for HIV prevention as pre-exposure prophylaxis (PrEP) across all PAHO member states in Latin America and the Caribbean. The company was incorporated in 1987 and is headquartered in Foster City, California.
Sector
Health Care
Industry
Biotechnology
Primary listing
Nasdaq
United States
CEO
Daniel Patrick O'Day
Founded
1987
Employees
17 000
Revenue / employee
1.7M USD
Next earnings
February 8, 2027 (estimated)
Institutional holders
- FMR LLC4.70%
- GEODE CAPITAL MANAGEMENT, LLC2.43%
- Bank of New York Mellon Corp1.19%
- Rest of the register91.68%
3 13F filings as of September 30, 2026: US managers above $100M, filed up to 45 days after quarter end. No insiders, no retail. A share on loan is declared by its lender and by whoever bought it from the short seller, so the total can exceed 100%.
Research uses the underlying stock’s market history. The purchase quote is calculated separately when you review your order.
52-week high
176.58 USD
52-week low
116.88 USD
1-year performance
38.71%
Rising
Year-to-date performance
38.60%
Rising
Drawdown
-3.85%
Near its high
Position in the 52-week range
89% of range
Against the world ETF
Over 26 years, from December 2000 to October 2026, the share did not clearly beat the world ETF once risk is accounted for. It earned much more, but shaking 1.9 times harder: once that risk is counted, its lead is thin.
$10,000 placed at the end of December 2000 are worth today
| Gilead Sciences | $964,930 |
| World ETF | $65,117 |
| S&P 500 | $91,204 |
| Risk-free placement | $15,894 |
The risk
- Shaking:the share moves 1.9 times as much as the world ETF.
- Worst fall:-43 % between July 2015 and May 2017. $10,000 placed at the top fell to $5,723. The world ETF, at worst: -53 %. Back to its high in 89 months.
Gilead Sciences earned 15 times as much as the world ETF since 2000
Value of $10,000 placed at the end of December 2000, dividends reinvested, in dollars
- Gilead Sciences: $964,930
- World ETF: $65,117
- S&P 500: $91,204
- Risk-free placement: $15,894
Based on past performance. This is not a recommendation.
Range: 167.53 USD - 196.36 USD (3 methods agree)
The price implies growth of 1.47% per year; the company grows at 25.00%.
Gross margin 80.0%, the company loses 12.4% of its revenue, ROIC -9.6%, ROE -22.3%.
Net margin
-12.44%
Negative
Sector -14.06%|S&P 13.40%
Gross margin
80.00%
Fair
Return on equity (ROE)
-22.34%
Negative
Sector -17.71%|S&P 17.06%
Return on invested capital (ROIC)
-9.59%
Negative
Free cash flow margin (FCF)
44.36%
Exceptional
Margin stability
12.1 pts
Very uneven
Revenue to net income
Growth
2.3/10Revenue up 6.7% over 1 year, 3.6% a year over 5, EPS 133.6% a year over 5.
Revenue (trailing 12 months)
31.1Md USD
Revenue growth (1y)
6.68%
Solid
Revenue growth (3y)
8.72%
Moderate
EPS growth (1y)
-20.22%
Declining
EPS CAGR (5y)
133.64%
Exceptional
EPS revisions (3 months)
—
Valuation
3.9/10The company loses money, so no valuation multiple can be read: a negative P/E is not a discount.
P/E (TTM)
—
N/A (loss)
Sector 31.0x|S&P 23.6x
Forward P/E
—
N/A (loss)
EV / EBITDA
15.7x
Fair
Sector 18.0x|S&P 15.5x
PEG
—
Sector -0.08|S&P 0.91
Fair value (reverse DCF)
178.30 USD
Fairly priced
Market cap
211Md USD
Financial strength
4.9/10Cash covers 30.3% of the debt, net debt/EBITDA 1.1x.
Net debt / EBITDA
1.1x
Solid
Gearing (net debt / equity)
141.11%
Stretched
Cash
8.0Md USD
Cash / market cap
3.78%
Tight
Cash / total debt
30.32%
Solid
Interest coverage
-2.3x
Stretched
Net debt
18.3Md USD
Equity
13.0Md USD
Closed daily candles, 2 years
Last close on November 11, 2026: 169.74 USD
- MM20163.00
- MM50154.39
- MM200141.44
- RSI 1462.2
Top panel: closed candles, 20, 50 and 200-day moving averages, with volume in grey. Bottom panel: 14-day RSI with dashed 30 and 70 levels.
200-day average slope, 1 month
+2.82%
200-day average slope, 3 months
+6.86%
50-day average slope, 1 month
+6.15%
Price structure
higher-low
Bullish RSI divergence
No
20-day volatility
2.10 % per day
Volatility change
+24.75%
Forecasts by fiscal year
| Fiscal year | EPS | Normalised EPS | Revenue | EBITDA | Net income |
|---|---|---|---|---|---|
| 2026 | -4.26 (11) | -0.98 (23) | 31 363 (25) | 4 982 (3) | -5 292 (7) |
| 2027 | 8.29 (12) | 10.12 (27) | 33 575 (25) | 19 195 (3) | 10 697 (7) |
Amounts in millions of USD, EPS in USD per share. In brackets, the number of analysts. Consensus as of November 11, 2026.
Same sub-industry: 416 companies behind the medians.
| # | Company | Code | Country | Overall / 10 | Fundamentals / 10 | Mkt cap | P/E | Net margin | Revenue growth | ROIC | Net debt / EBITDA | FCF yield | 1-year perf. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | ARGX | 6.6 | 6.1 | 60.3Md USD | 38.9x | 32.8 % | 81.8 % | 23.3 % | -4.1x | 1.8 % | 16.9 % | ||
| 2 | ONC | 6.6 | 6.6 | 47.2Md USD | 53.2x | 13.9 % | 34.0 % | 14.5 % | -4.4x | 3.1 % | 25.7 % | ||
| 3 | REGN | 6.4 | 6.1 | 99.2Md USD | 21.2x | 28.5 % | 36.3 % | 13.9 % | -1.3x | 3.9 % | 47.3 % | ||
| 4 | ABBV | 6.1 | 5.0 | 521Md USD | 50.8x | 15.6 % | 10.3 % | 16.1 % | 2.2x | 3.6 % | 34.7 % | ||
| 5 | VRTX | 5.6 | 4.1 | 139Md USD | 35.2x | 30.5 % | 10.4 % | 17.5 % | -0.9x | 2.3 % | 29.2 % | ||
| 6 | AMGN | 5.5 | 5.3 | 253Md USD | 27.2x | 24.1 % | 8.1 % | 14.7 % | 2.9x | 3.8 % | 44.7 % | ||
| 7 | CSL | 4.6 | 3.7 | 65.9Md USD | Not meaningful (loss) | -15.6 % | -2.8 % | -8.9 % | 1.8x | 4.3 % | 14.8 % | ||
| 8 | GILD | 4.2 | 2.9 | 211Md USD | Not meaningful (loss) | -12.4 % | 6.7 % | -9.6 % | 1.1x | 6.5 % | 38.7 % | ||
| 9 | MRNA | 3.3 | 1.3 | 101Md USD | Not meaningful (loss) | -110.5 % | 29.2 % | -26.5 % | 0.4x | -2.0 % | 896.8 % |
